262 related articles for article (PubMed ID: 31988978)
1. Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials.
Tyagarajan S; Spencer T; Smith J
Mol Ther Methods Clin Dev; 2020 Mar; 16():136-144. PubMed ID: 31988978
[TBL] [Abstract][Full Text] [Related]
2. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
3. Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Fong D; Tiwari R; Acker C; Clough L; Willert J
Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
[TBL] [Abstract][Full Text] [Related]
4. Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Ittershagen S; Ericson S; Eldjerou L; Shojaee A; Bleickardt E; Patel M; Taran T; Anak O; Hall C; Leung M; Roccoberton D; Salmon F; Fuchs M; Romanov V; Lebwohl D
Curr Hematol Malig Rep; 2019 Feb; 14(1):47-55. PubMed ID: 30666506
[TBL] [Abstract][Full Text] [Related]
5. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
Liu Y; Chen X; Han W; Zhang Y
Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
[TBL] [Abstract][Full Text] [Related]
6. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ; Bishop MR; Tam CS; Waller EK; Borchmann P; McGuirk JP; Jäger U; Jaglowski S; Andreadis C; Westin JR; Fleury I; Bachanova V; Foley SR; Ho PJ; Mielke S; Magenau JM; Holte H; Pantano S; Pacaud LB; Awasthi R; Chu J; Anak Ö; Salles G; Maziarz RT;
N Engl J Med; 2019 Jan; 380(1):45-56. PubMed ID: 30501490
[TBL] [Abstract][Full Text] [Related]
7. Tisagenlecleucel Therapy: Nursing Considerations for the Outpatient Setting.
Cunningham K; DiFilippo H; Henes K; Irwin LL; Napier E; Weber E
Semin Oncol Nurs; 2021 Aug; 37(4):151178. PubMed ID: 34340892
[TBL] [Abstract][Full Text] [Related]
8. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Awasthi R; Pacaud L; Waldron E; Tam CS; Jäger U; Borchmann P; Jaglowski S; Foley SR; van Besien K; Wagner-Johnston ND; Kersten MJ; Schuster SJ; Salles G; Maziarz RT; Anak Ö; Del Corral C; Chu J; Gershgorin I; Pruteanu-Malinici I; Chakraborty A; Mueller KT; Waller EK
Blood Adv; 2020 Feb; 4(3):560-572. PubMed ID: 32045475
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Mueller KT; Waldron E; Grupp SA; Levine JE; Laetsch TW; Pulsipher MA; Boyer MW; August KJ; Hamilton J; Awasthi R; Stein AM; Sickert D; Chakraborty A; Levine BL; June CH; Tomassian L; Shah SS; Leung M; Taran T; Wood PA; Maude SL
Clin Cancer Res; 2018 Dec; 24(24):6175-6184. PubMed ID: 30190371
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
11. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
Thudium Mueller K; Grupp SA; Maude SL; Levine JE; Pulsipher MA; Boyer MW; August KJ; Myers GD; Tam CS; Jaeger U; Foley SR; Borchmann P; Schuster SJ; Waller EK; Awasthi R; Potthoff B; Warren A; Waldron ER; McBlane F; Chassot-Agostinho A; Laetsch TW
Blood Adv; 2021 Dec; 5(23):4980-4991. PubMed ID: 34432863
[TBL] [Abstract][Full Text] [Related]
12. CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
Pacenta HL; Laetsch TW; John S
Paediatr Drugs; 2020 Feb; 22(1):1-11. PubMed ID: 31749131
[TBL] [Abstract][Full Text] [Related]
13. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Thomas X; Paubelle E
Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
Makita S; Imaizumi K; Kurosawa S; Tobinai K
Drugs Context; 2019; 8():212567. PubMed ID: 30815024
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
Lin JK; Lerman BJ; Barnes JI; Boursiquot BC; Tan YJ; Robinson AQL; Davis KL; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2018 Nov; 36(32):3192-3202. PubMed ID: 30212291
[TBL] [Abstract][Full Text] [Related]
16. Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date.
Zavras PD; Wang Y; Gandhi A; Lontos K; Delgoffe GM
Onco Targets Ther; 2019; 12():4543-4554. PubMed ID: 31354288
[TBL] [Abstract][Full Text] [Related]
17. Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Pediatr; 2018 Dec; 172(12):1161-1168. PubMed ID: 30304407
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe.
Buechner J; Kersten MJ; Fuchs M; Salmon F; Jäger U
Hemasphere; 2018; 2(1):e18. PubMed ID: 31723747
[TBL] [Abstract][Full Text] [Related]
19. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.
Hucks G; Rheingold SR
Blood Cancer J; 2019 Jan; 9(2):10. PubMed ID: 30670684
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
